{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:04:10Z","timestamp":1790345050284,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP25\/00036"],"award-info":[{"award-number":["CP25\/00036"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01094"],"award-info":[{"award-number":["PI20\/01094"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying reproducible biomarkers associated with treatment outcomes remains a major unmet clinical need in advanced non-small cell lung cancer (NSCLC). METLUNG evaluated whether plasma metabolomic profiling, alone or combined with clinical variables, could identify biomarkers associated with clinical response and survival outcomes in patients with NSCLC treated with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      METLUNG is a prospective observational cohort (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"98848959\">ISRCTN98848959<\/jats:ext-link>\n                      ) that enrolled 128 patients with stage III\u2013IV NSCLC eligible for immune checkpoint inhibitors between October 2020 and December 2022 at Hospital Universitari Sant Joan de Reus, Reus (Spain). Clinical response classification was based on Immune Response Evaluation Criteria in Solid Tumors criteria, and subsequent clinical and radiological course. Baseline plasma metabolomic profiling was followed by univariate analyses and multivariate modeling. Survival models were built using clinical variables, metabolomic variables, significant metabolites, and an integrated clinical\u2013metabolomic composite model. Predictive performance was evaluated using integrated area under the receiver operating characteristic curve and concordance index (C-index).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 127 evaluable patients, 52.8% achieved a clinical response. Most had adenocarcinoma (n=94), followed by squamous carcinoma (n=28). Treatment included first-line immunotherapy monotherapy (n=39), first-line chemo-immunotherapy (n=47), or second-line immunotherapy (n=41). Clinical response differed by sex and Eastern Cooperative Oncology Group performance status but showed no association with smoking history or PD-L1 expression.<\/jats:p>\n                    <jats:p>Univariate analyses identified 41 baseline metabolites associated with response, and 69 and 71 metabolites associated with progression-free survival and overall survival (OS), respectively. Five metabolites (histidine, citric acid, uracil, lactic acid, and sarcosine) remained consistently significant across all endpoints. Higher histidine and citric acid levels were associated with improved outcomes, whereas uracil, lactic acid, and sarcosine correlated with worse outcomes. The integrated clinical-metabolomic model showed the highest prognostic performance compared with clinical or metabolomic prognostic models alone, providing better early survival discrimination. In the immunotherapy monotherapy subgroup, only the integrated model was significant for OS, while metabolomic signatures showed stronger prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolomic profiling identified metabolic signatures associated with clinical response and survival outcomes in NSCLC patients treated with immune checkpoint inhibitors. An integrated clinical\u2013metabolomic model showed improved prognostic stratification, supporting the potential value of plasma metabolomics for patient risk stratification. These findings remain exploratory and require validation in independent, ideally multicenter, cohorts before clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN98848959\">ISRCTN98848959<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-016077","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:19Z","timestamp":1790343919000},"page":"e016077","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["METLUNG: plasma metabolomic profiling identifies metabolomic signatures associated with immunotherapy outcomes in non-small cell lung cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn98848959","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn98848959","registry":"10.18810\/isrctn"}],"author":[{"given":"Clara","family":"Luc\u00eda-Goz\u00e1lvez","sequence":"first","affiliation":[{"name":"Oncology, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"},{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Papandreou","sequence":"additional","affiliation":[{"name":"Neurosciences and Mental Health, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"},{"name":"Department of Nutrition and Dietetics Sciences, Hellenic Mediterranean University School of Health Sciences, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Badia","sequence":"additional","affiliation":[{"name":"Statistics Support Platform, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-4247","authenticated-orcid":false,"given":"Raquel","family":"Cumeras","sequence":"additional","affiliation":[{"name":"Oncology, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"},{"name":"Department of Electronic, Electrical and Automatic Engineering, Rovira i Virgili University, Tarragona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Peralta","sequence":"additional","affiliation":[{"name":"Oncology, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"},{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ed","sequence":"additional","affiliation":[{"name":"Oncology, Institut de Recerca Biom\u00e8dica Catalunya Sud (IRBCatSud), Reus, Spain"},{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vidaller","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Quintana","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Gum\u00e0","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Institut d\u2019Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"},{"name":"Department of Medicine and Surgery, Rovira i Virgili University Faculty of Medicine and Health Sciences, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092506450892000_14.9.e016077.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092506450892000_14.9.e016077.2","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN) . Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a. 2024. Available: https:\/\/redecan.org\/storage\/documents\/031b5800-a7fe-4c2b-8a09-a38d046365df.pdf"},{"key":"2026092506450892000_14.9.e016077.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021611","article-title":"Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis","volume":"8","author":"O\u2019Keeffe","year":"2018","journal-title":"BMJ Open"},{"key":"2026092506450892000_14.9.e016077.4","doi-asserted-by":"publisher","DOI":"10.1080\/09553000802635054"},{"key":"2026092506450892000_14.9.e016077.5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3892\/mco.2017.1277","article-title":"Asbestos-related lung cancers: A retrospective clinical and pathological study","volume":"7","author":"Uguen","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2026092506450892000_14.9.e016077.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02660"},{"key":"2026092506450892000_14.9.e016077.7","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.21.01497"},{"key":"2026092506450892000_14.9.e016077.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"2026092506450892000_14.9.e016077.9","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030320","article-title":"Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"2026092506450892000_14.9.e016077.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.03.004"},{"key":"2026092506450892000_14.9.e016077.11","first-page":"1312","article-title":"Biomarkers for immune checkpoint blockade in non-small cell lung cancer: current status and future directions","volume":"16","author":"Gettinger","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026092506450892000_14.9.e016077.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3314"},{"key":"2026092506450892000_14.9.e016077.13","doi-asserted-by":"publisher","DOI":"10.1038\/4551054a"},{"key":"2026092506450892000_14.9.e016077.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588"},{"key":"2026092506450892000_14.9.e016077.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1170-y"},{"key":"2026092506450892000_14.9.e016077.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2026092506450892000_14.9.e016077.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2026092506450892000_14.9.e016077.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"2026092506450892000_14.9.e016077.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2026092506450892000_14.9.e016077.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2026092506450892000_14.9.e016077.21","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026092506450892000_14.9.e016077.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.09.109"},{"key":"2026092506450892000_14.9.e016077.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1554871","article-title":"Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"2026092506450892000_14.9.e016077.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249980","article-title":"The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"key":"2026092506450892000_14.9.e016077.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101788","article-title":"Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies","volume":"38","author":"Vryza","year":"2023","journal-title":"Transl Oncol"},{"key":"2026092506450892000_14.9.e016077.26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026092506450892000_14.9.e016077.27","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026092506450892000_14.9.e016077.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01748"},{"key":"2026092506450892000_14.9.e016077.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-16788-7","article-title":"Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy","volume":"15","author":"Karao\u011flan","year":"2025","journal-title":"Sci Rep"},{"key":"2026092506450892000_14.9.e016077.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1479550","article-title":"Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"2026092506450892000_14.9.e016077.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-025-03430-3","article-title":"18F-FDG PET\/CT for prediction of PD-L1 expression and tumor mutational burden in non-small cell lung cancer: biomarkers prediction models development and immunotherapy responses verification","volume":"27","author":"Zhang","year":"2025","journal-title":"Respir Res"},{"key":"2026092506450892000_14.9.e016077.32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000045224","article-title":"Combined laboratory and imaging indicators to construct risk models for predicting immunotherapy efficacy and prognosis in non-small cell lung cancer: An observational study (STROBE compliant)","volume":"104","author":"Bai","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026092506450892000_14.9.e016077.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"2026092506450892000_14.9.e016077.34","doi-asserted-by":"crossref","first-page":"117823","DOI":"10.1016\/j.cca.2024.117823","article-title":"Metabolomics and lipidomics in non-small cell lung cancer","volume":"555","author":"Shi","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026092506450892000_14.9.e016077.35","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0375-3"},{"key":"2026092506450892000_14.9.e016077.36","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12369"},{"key":"2026092506450892000_14.9.e016077.37","doi-asserted-by":"crossref","first-page":"156334","DOI":"10.1016\/j.metabol.2025.156334","article-title":"Carboxylic acid metabolism in cancer: Mechanisms, microenvironment interactions, and therapeutic opportunities","volume":"171","author":"Bian","year":"2025","journal-title":"Metabolism"},{"key":"2026092506450892000_14.9.e016077.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384948","article-title":"A review of lactate-lactylation in malignancy: its potential in immunotherapy","volume":"15","author":"Zha","year":"2024","journal-title":"Front Immunol"},{"key":"2026092506450892000_14.9.e016077.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1332043","article-title":"Specific changes in amino acid profiles in monocytes of patients with breast, lung, colorectal and ovarian cancers","volume":"14","author":"Chagovets","year":"2023","journal-title":"Front Immunol"},{"key":"2026092506450892000_14.9.e016077.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.002"},{"key":"2026092506450892000_14.9.e016077.41","doi-asserted-by":"crossref","first-page":"2580S","DOI":"10.1093\/jn\/nxaa132","article-title":"Potential Benefits and Pitfalls of Histidine Supplementation for Cancer Therapy Enhancement","volume":"150","author":"Petrova","year":"2020","journal-title":"J Nutr"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-016077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:24Z","timestamp":1790343924000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-016077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-016077"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-016077","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}